Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Oncotype DX AR-V7 Nucleus Detect® Test

Identify your patients who may not respond to AR-targeted therapies1-4

Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next steps for treatment.

Confidently guide treatment decisions in mCRPC

Not all mCRPC patients respond to androgen receptor (AR)-targeted therapies, like abiraterone and enzalutamide.1 When AR-targeted therapy fails, acquired resistance could be the cause.1

Image shows a possible mCRPC treatment path

The only predictive and prognostic test for patients with mCRPC, the AR-V7 Nucleus Detect® test:

  • Accurately identifies patients who may not benefit from AR-targeted therapies2,3
  • Predicts improved overall survival with taxanes versus AR-targeted therapies2,3
  • Provides easy-to-interpret results (a positive or negative result)

Why the AR-V7 Nucleus Detect Test for Your mCRPC Patients?

The Oncotype DX AR-V7 Nucleus Detect test is an assay that identifies patients who may not respond to androgen receptor (AR)-targeted therapy and should receive chemotherapy or other therapies instead.1-4

Get fast results from a simple blood draw

The Oncotype DX AR-V7 Nucleus Detect test is a liquid biopsy assay that analyzes circulating tumor cells in a patient's blood. No intrusive or complicated procedures are required. The results are reported to the ordering physician through a secure portal, confirming the patient as either AR-V7-positive (AR-V7+) or AR-V7-negative (AR-V7-).

Is your patient eligible?

The Oncotype DX AR-V7 Nucleus Detect test is for patients who:

  • Have confirmed mCRPC
  • Have received and failed AR-targeted therapy
  • Are considering additional AR-targeted therapies

Coverage and financial assistance

The AR-V7 Nucleus Detect test is widely accessible, with minimal out-of-pocket costs for most patients.*

*The Oncotype DX AR-V7 Nucleus Detect test is reported on claims with the unique Current Procedural Terminology (CPT) code, 81479.

Order a test

We make your ordering experience efficient. Tests are ordered through the online physician portal, and we’ll help you every step of the way.